Academic Journal
Investigation and validation of prognostic features associated with transient receptor potential channel genes in gastric cancer.
| Τίτλος: | Investigation and validation of prognostic features associated with transient receptor potential channel genes in gastric cancer. |
|---|---|
| Συγγραφείς: | Zhao J; Department of Radiotherapye, The Second Hospital of Lanzhou University, Lanzhou, China.; Department of Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou City, Gansu Province, China., Kang H; Department of Radiotherapye, The Second Hospital of Lanzhou University, Lanzhou, China., Pan J; Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, China., Sun P; Department of Radiotherapye, The Second Hospital of Lanzhou University, Lanzhou, China. |
| Πηγή: | PeerJ [PeerJ] 2026 Aug 11; Vol. 14, pp. e21468. Date of Electronic Publication: 2026 Aug 11 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: PeerJ Inc Country of Publication: United States NLM ID: 101603425 Publication Model: eCollection Cited Medium: Internet ISSN: 2167-8359 (Electronic) Linking ISSN: 21678359 NLM ISO Abbreviation: PeerJ Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Corte Madera, CA : PeerJ Inc. |
| Ιατρικοί όροι (MeSH): | Stomach Neoplasms*/genetics , Stomach Neoplasms*/pathology , Stomach Neoplasms*/mortality , Transient Receptor Potential Channels*/genetics , Adenocarcinoma*/genetics, Biomarkers, Tumor/genetics ; Humans ; Prognosis ; Gene Expression Regulation, Neoplastic ; Gene Regulatory Networks |
| Περίληψη: | Background: An increasing body of evidence suggests an association between transient receptor potential (TRP) channel s and cancer development; however, a systematic evaluation of the combined prognostic value of TRP channel-related genes (TRGs) in gastric cancer (GC) has not been conducted. Methods: Data were obtained from The Cancer Genome Atlas Stomach Adenocarcinoma, GSE84433, and TRGs. Prognostic genes related to TRP channels and GC were screened, and a risk model was constructed. Functional analysis, immune correlation analysis, and molecular regulatory network construction were performed to identify mechanisms associated with GC prognosis. Finally, the expression of prognostic genes was preliminarily assessed in clinical samples using reverse transcription quantitative polymerase chain reaction (RT-qPCR) for exploratory validation. Results: Seven genes associated with GC prognosis (5-hydroxytryptamine 2C receptor (HTR2C), MAGEA11, MAGEA3, aspartoacylase (ASPA), GAD1, Hedgehog-interacting protein (HHIP), and AHNAK) were identified. A risk model constructed from these genes demonstrated potential prognostic value for patient outcomes. A close association was observed between these genes and the differential abundance of immune cells. The strongest negative correlation was observed between AHNAK and T follicular helper cells. In addition, the prognostic genes were significantly negatively correlated with CD274, which is an immune checkpoint gene. Moreover, complex regulatory relationships among prognostic genes were observed in the regulatory network. Computational analysis predicted regulatory interactions, such as the regulation of AHNAK by EPB41L4A-AS1 and ERICD via hsa-miR-106a-5p. Finally, quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis revealed that the expression pattern of MAGEA11 was consistent with that observed in public databases. Conclusions: Seven prognostic genes (HTR2C, MAGEA11, MAGEA3, ASPA, GAD1, HHIP, and AHNAK) related to TRP channels were identified in GC. These findings provide insight into potential prognostic mechanisms and a basis for further studies on their roles in GC biology. (©2026 Zhao et al.) |
| Competing Interests: | The authors declare there are no competing interests. |
| References: | Int Immunopharmacol. 2021 Sep;98:107889. (PMID: 34174699) Mil Med Res. 2023 Jun 5;10(1):25. (PMID: 37271807) Front Oncol. 2021 Dec 14;11:784925. (PMID: 34970496) BMC Neurosci. 2025 Jan 13;26(1):3. (PMID: 39806309) Mol Biol (Mosk). 2012 Jan-Feb;46(1):166-75. (PMID: 22642115) Sci Rep. 2024 Mar 30;14(1):7573. (PMID: 38555374) Front Oncol. 2020 Dec 22;10:1667. (PMID: 33415068) Front Oncol. 2021 Mar 17;10:626912. (PMID: 33816214) BMC Cancer. 2023 Jun 30;23(1):604. (PMID: 37391709) Thorac Cancer. 2023 Aug;14(22):2093-2104. (PMID: 37349884) Biomolecules. 2023 Oct 22;13(10):. (PMID: 37892239) Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2512-22. (PMID: 26072287) Cell Calcium. 2019 Sep;82:102053. (PMID: 31279156) World J Gastrointest Oncol. 2024 Jun 15;16(6):2862-2864. (PMID: 38994148) Int J Mol Sci. 2025 Apr 11;26(8):. (PMID: 40332161) Cancer Med. 2019 Aug;8(10):4699-4708. (PMID: 31270941) Biomark Res. 2022 Aug 30;10(1):67. (PMID: 36042469) Cancer Manag Res. 2024 May 08;16:431-444. (PMID: 38751848) J Pers Med. 2022 Mar 16;12(3):. (PMID: 35330477) J Cell Sci. 2021 Jul 1;134(13):. (PMID: 34254641) Aging (Albany NY). 2024 Jan 4;16(1):285-298. (PMID: 38180746) Appl Biochem Biotechnol. 2024 Jan;196(1):1-17. (PMID: 37097403) Int J Biol Macromol. 2025 Apr;301:140445. (PMID: 39884598) Endocrinology. 2024 May 27;165(7):. (PMID: 38815086) Neural Regen Res. 2023 Aug;18(8):1652-1656. (PMID: 36751775) Cell Calcium. 2023 Jul;113:102759. (PMID: 37210868) CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766) Heliyon. 2024 Jun 27;10(13):e33687. (PMID: 39040243) Int J Mol Sci. 2024 Jul 30;25(15):. (PMID: 39125864) Front Cell Neurosci. 2015 Mar 17;9:86. (PMID: 25852478) Mech Ageing Dev. 2025 Dec;228:112118. (PMID: 41067507) Indian J Clin Biochem. 2025 Jan;40(1):46-58. (PMID: 39835242) Front Genet. 2024 May 09;15:1391842. (PMID: 38784033) Cancer Immunol Immunother. 2024 Sep 5;73(11):225. (PMID: 39235488) Ann Rheum Dis. 2022 Jul;81(7):1006-1012. (PMID: 35414518) Nat Med. 2022 Dec;28(12):2537-2546. (PMID: 36536256) Dig Dis Sci. 2022 Aug;67(8):3742-3752. (PMID: 34427817) Cell Oncol (Dordr). 2024 Jun;47(3):833-850. (PMID: 37962808) Front Oncol. 2022 Jul 07;12:941283. (PMID: 35875096) J Immunother. 2013 Feb;36(2):133-51. (PMID: 23377668) Int Immunol. 2026 Jan 14;38(1):56-67. (PMID: 40916279) Front Genet. 2022 Sep 15;13:905650. (PMID: 36186485) Medicine (Baltimore). 2023 Mar 10;102(10):e33228. (PMID: 36897679) BMC Med Genomics. 2022 Jul 13;15(1):156. (PMID: 35831825) Acta Biochim Biophys Sin (Shanghai). 2024 May 11;56(7):957-962. (PMID: 38734935) Lancet Oncol. 2022 Feb;23(2):234-247. (PMID: 35030335) Cancers (Basel). 2024 Jan 05;16(2):. (PMID: 38254738) Aging (Albany NY). 2022 Nov 8;14(23):9579-9598. (PMID: 36367777) Int J Mol Sci. 2022 Aug 12;23(16):. (PMID: 36012311) Lancet. 2017 Dec 2;390(10111):2461-2471. (PMID: 28993052) Ann Surg Oncol. 2022 May;29(5):2944-2956. (PMID: 34855064) |
| Contributed Indexing: | Keywords: Gastric carcinoma; Prognostic genes; Stomach adenocarcinoma; TCGA-STAD; Transient receptor potential channel |
| Substance Nomenclature: | 0 (Transient Receptor Potential Channels) 0 (Biomarkers, Tumor) |
| Entry Date(s): | Date Created: 20260815 Date Completed: 20260815 Latest Revision: 20260816 |
| Update Code: | 20260816 |
| PubMed Central ID: | PMC13475387 |
| DOI: | 10.7717/peerj.21468 |
| PMID: | 42602890 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2167-8359 |
|---|---|
| DOI: | 10.7717/peerj.21468 |